Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
|02/12/18 3:00 p.m. ET|
|There are currently no items available.|Data provided by Nasdaq. Minimum 15 minutes delayed.
| Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.|